India's over-dependence on China for key pharma raw material worrying, says ASSOCHAM paper

19 October 2016

India may have emerged as a key supplier of generic and affordable medicine for the world market, its overwhelming dependence on China for a crucial raw material, or active pharmaceutical ingredient (API), to the extent of over 65% of the requirement, has emerged as a main worrying area, an ASSOCHAM (The Associated Chambers of Commerce & Industry of India) and business management consultancy RNCOS joint paper has noted.

This is all the more disconcerting in the face of louder narrative against reducing trade gap with China which is well over $51 billion, adds the ASSOCHAM study.

While rapid growth in new medical technologies is spurring the demand for APIs worldwide today with the increased import of raw pharma ingredients from the emerging markets, India’s rising dependence on imports from China for many APIs that go into the making of a number of essential drugs has been cited as an area of concern for the policy makers.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK